TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8718917
Drug: Pressure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure treatment applied for 10 sec prior to injection
Study: 8718917
Drug: Standard injection
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard injection with no pressure applied
Study: 6093487
Drug: 1,25(OH)2D3/l alpha‐OHD3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)2D3/l alpha‐OHD3 (0.25 micrograms/day)
Study: 24508899
Drug: 3-day faropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day faropenem treatment
Study: 24508899
Drug: 7-day faropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day faropenem treatment
Study: 22953994
Drug: Group-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based behavioral exercise program (weekly sessions and homework for 6 months)
Study: 20699432
Drug: Euglycemia (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (5.5 mmol/l)
Study: 20699432
Drug: Progressive hypoglycemia
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive hypoglycemia (3.9-2.5 mmol/l)
Study: 1678650
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg intravenously three times a day until the fourth postoperative day (n = 10)
Study: 31831028
Drug: Dienogest (DNG)
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dienogest (DNG) treatment
Study: 31831028
Drug: Standard controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard controlled ovarian hyperstimulation with GnRH agonist
Study: 25525051
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) inactivated influenza vaccine (IIV)
Study: 25525051
Drug: Standard-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (SD) inactivated influenza vaccine (IIV)
Study: 15504128
Drug: Terbinafine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine treatment (62.5 mg/day for <20 kg, 125 mg/day for 20-40 kg, 250 mg/day for >40 kg)
Study: 11223322
Drug: High-dose acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acyclovir
Study: 8279252
Drug: Epidural bolus
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bolus injection of 4 mg morphine in 2 ml volume (Group I)
Study: 8279252
Drug: Epidural bolus
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bolus injection of 4 mg morphine in 10 ml volume (Group II)
Study: 8279252
Drug: Epidural bolus
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bolus injection of 4 mg morphine in 20 ml volume (Group III)
Study: 26786149
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin at 0.07 IU/kg
Study: 20394040
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg twice daily
Study: 20394040
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg initially and then 75 mg once daily
Study: 16311295
Drug: Mild ovarian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild ovarian stimulation with GnRH antagonist co‐treatment and single embryo transfer (SET)
Study: 16311295
Drug: Conventional GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional GnRH agonist long protocol ovarian stimulation with double embryo transfer (DET)
Study: 9546928
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg three times daily
Study: 9546928
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg three times daily (after excluding patients on potassium-losing diuretics)
Study: 9546928
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after excluding patients on potassium-losing diuretics)
Study: 1449116
Drug: Infusional 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusional 5-fluorouracil (5-FU) at 350 mg/m2 per day for 2 weeks with a 2-week rest period on a monthly basis
Study: 1449116
Drug: Bolus 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus 5-fluorouracil (5-FU) at 400-450 mg/m2 for 5 days every 28 days
Study: 2931840
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg twice a day)
Study: 2931840
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg twice a day)
Study: 22075320
Drug: Renin-angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system (RAS) inhibitors
Study: 29808753
Drug: No RAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: No RAS inhibitors (Control)
Study: 26841258
Drug: Teriparatide (TPTD)
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide (TPTD) 20 μg/day (s.c. injection)
Study: 26841258
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid (ZOL) 5 mg/year (i.v. infusion)
Study: 23017527
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg mirodenafil once daily
Study: 2065926
Drug: CCK‐8 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK‐8 (20 pmol.kg‐1.h‐1) after saline meal (0.154 mol/L)
Study: 6807248
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sublingual nifedipine (N)
Study: 6807248
Drug: 1 mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/Kg intravenous acebutolol (A)
Study: 6807248
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sublingual nifedipine (N) and 1 mg/Kg intravenous acebutolol (A)
Study: 27677865
Drug: Grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass pollen nasal spray
Study: 20816042
Drug: Armodafinil 200
Normalized name: armodafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 200 mg
Study: 19909829
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate (2.5 mg daily)
Study: 19084450
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate (20 mg intermittently)
Study: 31693129
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate
Study: 12587688
Drug: Artichoke leaf
Normalized name: artichoke leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke leaf extract (ALE) 320 mg daily
Study: 12587688
Drug: Artichoke leaf
Normalized name: artichoke leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke leaf extract (ALE) 640 mg daily
Study: 8287869
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg trimetazidine as an intravenous (i.v.) bolus followed by an infusion of trimetazidine at 60 mg.24 h‐1 for 48 h (n = 69)
Study: 3788761
Drug: Mexiletine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (5 to 10 mg/min until >= 95% VPD suppression or total 450 mg, average loading dose 4.4 mg/kg, infusion rate 0.1 mg/kg/min)
Study: 3788761
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg/kg over 3 minutes, with a second bolus if >= 95% suppression not achieved after 10 minutes)
Study: 12597674
Drug: Progressive Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive Muscle Relaxation (PMR) training once a week for 4 weeks, practiced at home daily.
Study: 10334425
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg q.d.)
Study: 1721246
Drug: Bradykinin (BK)
Normalized name: dimethicone
DrugBank: Bradykinin (DB12126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin (BK) after withdrawal of ACE inhibitors
Study: 30650480
Drug: Raw rhubarbs
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw rhubarbs by intranasal jejuna injection, 100 mL each time, twice per day for 3-7 days
Study: 24918563
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment gel
Study: 23092876
Drug: Autologous costimulated
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous costimulated T-cell product administered on day 2
Study: 23092876
Drug: T cells
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cells administered on day 90
Study: 14647963
Drug: Amisulpride (50‐1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (50‐1200 mg/day)
Study: 14647963
Drug: Amisulpride (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (mean daily doses below 400 mg/day)
Study: 11589262
Drug: Cerivastatin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.1 mg to 0.4 mg
Study: 11589262
Drug: Branded Pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded Pravastatin 10 mg to 40 mg
Study: 9700516
Drug: Methylphenidate (M
Normalized name: METHYLPHENIDATE (MALLINCK) 27MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (M = 26.92 mg/day = 0.78 mg/kg/day)
Study: 22305
Drug: Aspirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (600 mg in 1 dl of isotonic saline)
Study: 28045625
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy after 2 to 4 weeks of neoadjuvant aromatase inhibitor therapy (anastrozole, exemestane, or letrozole)
Study: 28045625
Drug: Neoadjuvant aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant aromatase inhibitor therapy
Study: 20707872
Drug: Dental health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental health program including fluoride varnish applied twice per year for 2 years, advocacy for water consumption and daily tooth cleaning with toothpaste, community dental health promotion, and training for primary health care workers in preventive dental care.
Study: 19539184
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein supplementation during hemodialysis and peritoneal dialysis
Study: 19539184
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein supplementation
Study: 19539184
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (protein supplementation and control)
Study: 15327558
Drug: HP cream
Normalized name: capsaicin Topical Cream [Capzasin-HP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP cream and adapalene 0.1% gel (group HP + A)
Study: 15327558
Drug: BP cream
Normalized name: Oral Cream
DrugBank: Cyclomethicone 5 (DB11244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP cream and adapalene 0.1% gel (group BP + A)
Study: 11009278
Drug: Enoxaparin low
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin low molecular weight heparin
Study: 9015035
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone (6 mg)
Study: 9015035
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (8 mg)
Study: 3526143
Drug: Ganglioside therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganglioside therapy (Cronassial, 40 mg daily)
Study: 21074334
Drug: Image-guided radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Image-guided radiation therapy (IGRT) using intraprostatic fiducials and Varian's Offline Review image analysis package.
Study: 3213064
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy for 2 weeks
Study: 23901675
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy for 4 weeks
Study: 3213064
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Acupuncture and Physical Therapy)
Study: 30371925
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg orally)
Study: 30371925
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 µg/kg IV bolus, followed by 0.5 µg/kg/h infusion)
Study: 30371925
Drug: Pregabalin and
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin and Dexmedetomidine (combined treatment)
Study: 21884017
Drug: etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 60 or 90 mg daily
Study: 21884017
Drug: diclofenac 150
Normalized name: diclofenac sodium 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 150 mg daily
Study: 20099399
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor strategy
Study: 9737815
Drug: Oral eprosartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral eprosartan (300 mg) under fasting conditions
Study: 9737815
Drug: Oral eprosartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral eprosartan (300 mg) following a high-fat breakfast
Study: 9737815
Drug: Intravenous eprosartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous eprosartan (20 mg)
Study: 8296748
Drug: Betaxolol 20
Normalized name: betaxolol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 20 mg every day
Study: 29136037
Drug: IV VRC01
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV VRC01 (40 mg/kg loading dose followed by five 20 mg/kg doses every 4 weeks)
Study: 29136037
Drug: IV VRC01
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV VRC01 (30 mg/kg doses every 8 weeks)
Study: 29136037
Drug: IV VRC01
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV VRC01 (10 mg/kg doses every 8 weeks)
Study: 29136037
Drug: SC VRC01
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC VRC01 (5 mg/kg every 2 weeks)
Study: 21167685
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (WP) formula; 35 kcal/kg/d and 1.2 g of protein/kg/d for 5 days
Study: 21167685
Drug: Casein formula;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein formula; 35 kcal/kg/d and 1.2 g of protein/kg/d for 5 days
Study: 17401538
Drug: Reboxetine (RBX)
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (RBX) 4 mg twice a day for 4 days preceded by 2 mg twice a day for 2 days
Study: 15527198
Drug: Qi-therapy (nine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi-therapy (nine sessions over two menstrual cycles)
Study: 11137652
Drug: Ambisome (amphotericin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambisome (amphotericin B lipid complex) at a dose of 15mg/kg body weight infused over 2h as a single dose
Study: 11137652
Drug: amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amphotericin B deoxycholate at a dose of 1mg/kg body infused for 2h for 20 days
Study: 15845315
Drug: Standard Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Cognitive Behavioral Therapy (CBT)
Study: 30611722
Drug: NT-proBNP-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP-guided treatment
Study: 12825133
Drug: Interferon alpha2b
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha2b + Cyclosporin A (200 mg daily for the first 4 weeks and 100 mg daily for the following 20 weeks)
Study: 12825133
Drug: Interferon alpha2b
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha2b (monotherapy)
Study: 362094
Drug: Topical glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glycopyrrolate (0.5% and 1.0%)
Study: 362094
Drug: Topical scopolamine
Normalized name: scopolamine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical scopolamine
Study: 362094
Drug: Commercial topical
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial topical antiperspirants
Study: 25563737
Drug: Whey protein-enriched
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein-enriched preload beverage (300 ml, 1300 kJ, 45 g)
Study: 23926573
Drug: JNJ-37822681 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-37822681 (10 mg, 20 mg, or 30 mg, twice daily)
Study: 23926573
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 mg/d during week 1; 15 mg/d after week 1)
Study: 23926573
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 weeks followed by 6 weeks of olanzapine, 15 mg/d)
Study: 11051229
Drug: Liquid preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid preparation of DFMO at daily dose 0.5 gram/m2
Study: 11051229
Drug: Tablet preparation
Normalized name: Digitalis preparation Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet preparation of DFMO at daily dose 0.5 gram/m2
Study: 7693506
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg via metered dose inhaler)
Study: 28472255
Drug: Intensified antituberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified antituberculosis regimen (15 mg/kg/day rifampicin and 20 mg/kg/day levofloxacin for the first 8 weeks)
Study: 28472255
Drug: Standard 9-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 9-month antituberculosis regimen (10 mg/kg/day rifampicin)
Study: 17133774
Drug: Valdecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib (40 mg twice daily on day 1 followed by 40 mg once daily on days 2‐7)
Study: 12642564
Drug: Self-reported home
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported home safety practices (using smoke alarms, stair gates, syrup of ipecac)
Study: 3395307
Drug: Synthetic food
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic food colourings (50 mg of tartrazine or carmoisine for 2 weeks each)
Study: 31339245
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable antipsychotics (LAI AP)
Study: 6345478
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum granules, 15 g/d for 3 months
Study: 26150193
Drug: First-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation drug-eluting stent
Study: 21928127
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg MgSO(4) plus 15 mg bupivacaine 0.5%
Study: 21928127
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg bupivacaine 0.5% with 0.2 ml normal saline (control group)
Study: 17024872
Drug: Tandem autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem autologous transplants followed by maintenance therapy
Study: 17024872
Drug: Sequential autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential autologous transplants followed by nonmyeloablative allotransplants
Study: 17024872
Drug: Induction and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction and/or consolidation treatments
Study: 15022177
Drug: Harpagophytum extracts
Normalized name: Harpagophytum procumbens whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harpagophytum extracts with 50-60 mg harpagoside daily
Study: 15022177
Drug: Proprietary ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proprietary ethanol extract with lower harpagoside dosage
Study: 10893344
Drug: 1 mU
Normalized name: benzocaine/cetalkonium 5-1 MUCOUS MEM TROCHE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mU x kg(‐1) x min(‐1) insulin infusion for 180 min
Study: 10893344
Drug: 5 mU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mU x kg(‐1) x min(‐1) insulin infusion for 180 min
Study: 2252045
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (325 mg on alternate days)
Study: 6090014
Drug: Doxorubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (40 mg/m2 iv every 3 weeks) and Mitomycin (12 mg/m2 iv every 6 weeks)
Study: 6090014
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m2 iv every 3 weeks X 3, then every 6 weeks) and Etoposide (80 mg/m2 iv on Days 1‐3 every 3 weeks X 3, then every 6 weeks)
Study: 22410021
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg per hr after an induction bolus of 2 mg/kg)
Study: 22410021
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (midazolam 0.2 mg/kg for induction without intravenous anesthetic infusion for maintenance)
Study: 15993354
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic treatment